Table 1.
Comparison of baseline characteristics between the 30-day survival and 30-day mortality subgroup
| Characteristics | Total (n = 440) (%) |
30-day survival (n = 300) (%) | 30-day mortality (n = 140) (%) |
p value* |
|---|---|---|---|---|
| Age (Years) | 49.48 (± 14.73) | 49.91(± 14.85) | 48.87(± 14.95) | 0.109 |
| Gender | 0.120 | |||
|
Male Female |
206(46.82) 234(53.18) |
133 (44.33) 167(55.66) |
73(52.14) 67(47.85) |
|
| Cancer status | 0.352 | |||
|
Recent Progression Recurrence Remission |
255(47.10) 84(15.50) 66(12.25) 35(6.55) |
181(60.36) 44(14.72) 41(13.73) 34(11.37) |
74(52.92) 40(28.64) 25(17.93) 1(0.71) |
|
| Types of cancer | 0.018* | |||
|
Solid tumour Haematological |
375(85.22) 65(14.88) |
264(88.00) 36(12.00) |
111(79.30) 29(20.70) |
|
| Stages of cancer | < 0.001* | |||
|
I II III IV Unknown |
27(6.10) 157(35.70) 146(33.20) 42(9.50) 68(15.50) |
26(8.72) 114(38.00) 100(33.38) 22(7.33) 38(12.77) |
1(0.74) 43(30.76) 46(32.90) 20(14.31) 30(21.49) |
|
| Histological classification | 0.217 | |||
|
Carcinoma Leukaemia Sarcoma Myeloma Lymphoma Mixed types Melanoma |
341(77.56) 55(12.52) 18(4.12) 11(2.50) 07(1.64) 04(1.00) 03(0.86) |
242(80.73) 29(9.74) 11(1.33) 09(3.72) 04(3.09) 01(1.010) 03(0.30) |
99(70.70) 26(18.68) 07(5.01) 03(2.11) 03(2.13) 02(1.47) 00(0) |
|
| Comorbidities | 0.201 | |||
|
Hypertension Diabetes mellitus Hypertension + Diabetes Hypothyroidism |
57(12.95) 37(08.40) 44(10.00) 46(10.45%) |
40(13.39) 27(09.00) 26(8.71) 34(11.33) |
17(25.02) 10(07.18) 18(12.85) 12(8.57) |
|
| History (within 3 months) | ||||
|
Surgery Radiation Chemotherapy |
129(29.33) 75(17.00) 164(37.37) |
88(29.32) 49(16.00) 109(36.00) |
41(29.28) 26(18.57) 55(39.28) |
0.922 0.589 0.494 |
| Treatment received | 0.004* | |||
|
Chemotherapy alone Radiotherapy alone Surgery alone Chemotherapy + radiotherapy Other |
148(33.60) 24(5.50) 116(26.40) 26(5.90) 126(28.64) |
98(32.72) 16(5.38) 93(31.00) 21(7.01) 72(24.09) |
50(35.76) 8(5.72) 23(16.42) 05(3.64) 54(37.86) |
|
| Invasive devices | ||||
|
Foley catheter Ryle’s tube Central venous catheter |
274(62.35) 143(32.55) 33(7.50) |
162(59.12) 69(15.68) 10 (2.72) |
112(40.88) 74(16.81) 23(5.22) |
< 0.001* < 0.001* < 0.001* |
| NCI category | < 0.001* | |||
|
0 I II III IV Neutrophilia |
140(31.82) 12(2.75) 7(1.64) 11(2.52) 41(9.302) 229(52.03) |
117(39.23) 8(2.72) 5(1.78) 8(2.70) 21(7.00) 141(47.45) |
23(16.47) 4(2.92) 2(1.43) 3(2.12) 20(14.36) 88(62.85) |
|
| MASCC risk score | < 0.001* | |||
|
High risk (< 21) Low risk (> 21) |
174(38.46) 266(59.12) |
32(31.30) 103(65.30) |
142(68.70) 163(34.70) |
*Categorical variables among survival and non-survival subgroups were compared using the Chi-square/Fisher’s exact test. Continuous variable was compared using independent sample t test. All significance tests were two-tailed, with a p value less than 0.05 indicating statistical significance, and such p values are shown as star in superscript